Catalog No.
EHH72401
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Met1-Pro141
Predicted molecular weight
26.32 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q495A1
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
VSTM3, TIGIT, V-set and transmembrane domain-containing protein 3, VSIG9, V-set and immunoglobulin domain-containing protein 9, T-cell immunoreceptor with Ig and ITIM domains
TIGIT as an emerging immune checkpoint. PMID: 31828774
TIGIT in cancer immunotherapy. PMID: 32900861
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. PMID: 28258695
Tim-3, Lag-3, and TIGIT. PMID: 28900677
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. PMID: 27192565
TIGIT: a novel immunotherapy target moving from bench to bedside. PMID: 30232519
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. PMID: 25465800
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. PMID: 29915296
Targeting the "PVR-TIGIT axis" with immune checkpoint therapies. PMID: 32489646
Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. PMID: 27620276
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. PMID: 27793572
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. PMID: 31234588
The relationship between TIGIT(+) regulatory T cells and autoimmune disease. PMID: 32172208
Immune checkpoint targeting TIGIT in hepatocellular carcinoma. PMID: 32774695
CD155T/TIGIT Signaling Regulates CD8(+) T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer. PMID: 28883004
Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. PMID: 30733837
Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma. PMID: 31485637
TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. PMID: 25866972
TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma. PMID: 29986909
CD226(hi)CD8(+) T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy. PMID: 32265229
CD155/TIGIT, a novel immune checkpoint in human cancers (Review). PMID: 33469677
Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. PMID: 32275969
Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma. PMID: 31387897
TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma. PMID: 32631956
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. PMID: 32591463
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. PMID: 30221069
Intratumoral TIGIT(+) CD8(+) T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer. PMID: 32817209
For research use only. Not for human or drug use.
